CAS: 92077-78-6; Cilazapril Monohydrate

该化合物是一种主要用于治疗高血压和心脏衰竭的抗血管素抗酶素(ACE)抑制剂;一种在水中溶解的白白白脱白结晶粉,并展示一种反映其单水化形态的分子式;该物质通过阻止将血管素I转化为血管素II,导致血管消化和降低血压;Cilazapril的特点是它有能力改善心功能和减少心血管事件的风险;单水化合物形式表明存在一种与每一种可影响其稳定性和溶解性的硅酸盐分子相关的水分子;就致癌物质而言,硅酸酯是一种药物,在身体中转化成其活性形态,即硅酸丙酸盐;由于超血糖等潜在的副作用,必须监测服用这种药物的病人的肾功能和钾含量.总体而言,西拉扎pril单水酸盐是一种宝贵的治疗剂,用于管理心血管疾病.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    📜在 盐酸体系中,用 四氢呋喃,水 作为反应溶剂,化学反应 16.0H,以89%的收率获得产物西拉普利
    参考文献:一种含六氢哒嗪酸结构的西拉普利的合成方 法
    标题:一种含六氢哒嗪酸结构的西拉普利的合成方 法
    摘要:本发明公开了一种含六氢哒嗪酸结构的西拉普利的简便合成方法,(1S,9S)‑9‑氨基‑10‑氧代‑6H‑哒嗪并[1,2‑a][1,2]二氮杂‑1‑羧酸叔丁酯(ⅱ)与(R)‑2‑羟基苯丁酸乙酯(ⅲ)在0~60°C,三苯基膦,偶氮二羧酸二酯的作用下发生mitsunobu缩合反应,反应生成(1S,9S)‑9‑[(1S)‑乙氧羰基‑3‑苯丙氨基]八氢‑10‑氧代‑6H‑哒嗪并[1,2‑a][1,2]二氮杂‑1‑羧酸叔丁酯(ⅳ)和(1S,9S)‑9‑[[(1S)‑乙氧羰基‑3‑苯丙基]氨基]八氢‑10‑氧代‑6H‑哒嗪并[1,2‑a][1,2]二氮杂‑1‑羧酸叔丁酯三苯基磷盐(ⅴ)的混合物,该混合物在盐酸水溶液作用下,得到西拉普利粗品,随后经重结晶后得到西拉普利(ⅰ).本发明的合成方法减少了提纯操作步骤,操作简单,避免了昂贵的三氟甲磺酸酐,以及具有难闻气味的吡啶的使用,适合工业化生产.

    海关参考信息

    专利信息


    专利号:US-9353057-B2
    优先权日:2003-12-30
    标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
    发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
    权利人:XENOPORT INC
    摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-7094920-B2
    优先权日:2001-05-21
    标 题 :Stereoselective synthesis of 2-hydroxy-4-phenylbutyric acid esters
    发明人:TIKARE RAVEENDRA KHANDURAO
    权利人:FERMENTA BIOTECH LTD
    摘要:A process is described for the stereospecific preparation of an ester of formula (I): wherein * signifies the (R) stereoisomer; R 1 is selected from C 1-6 alkyl, preferably ethyl; and R 2 is hydrogen, a protecting group or a leaving group which process comprises reaction of a nitrile of formula (II): wherein * signifies the (R) stereoisonomer; and Ph is the phenyl group C 6 H 5 with a solution of an inorganic acid in an alcohol and optional conversion of the compound of formula (I) wherein R 2 is H so prepared to any other desired compound of formula (I) by standard methods in the art. The compounds of formula (I) are chiral esters, useful as intermediates in the synthesis of the family of acetylcholine esterase (ACE) inhibitors known as “prilsâ€?, such as lisinopril, cilazapril, enalapril, benazepril, ramipril, delapril, enalaprilat, imidapril, spirapril, trandolapril and others.n n*n nPh-CH 2 —CH 2 —CH(OR 2 )—COOR 1   (I)n n*n nPh-CH 2 —CH 2 —CH(H)—CN  (II)

    专利号:US-8431712-B2
    优先权日:2004-02-09
    标 题 :Methods for the synthesis of pyridoxamine
    发明人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT
    权利人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT; NEPHROGENEX INC
    摘要:The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): n nand salts thereof.n nThe invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.

    专利号:US-6632942-B2
    优先权日:2000-05-04
    标题:Asymmetric synthesis of piperazic acid and derivatives thereof
    发明人:ROBIDOUX ANDREA L C; SERAFINI SIRO; DIETERICH PETRA; LEONARDI STEFANIA; STIBBARD JOHN
    权利人:VERTEX PHARMA
    摘要:This invention provides a concise, asymmetric synthesis of piperazic acid and derivatives thereof, whereby either the (3S)- or (3R)-enantiomeric form may be obtained with high optical purity. (3S)-piperazic acid is derived from D-glutamic acid through an (R)-2,5-dihydroxyvalerate ester intermediate. After the hydroxy groups are converted to suitable leaving groups, such as mesylates, the ester is treated with a bis-protected hydrazine to provide the desired (3S)-piperazic acid derivative. The (3R) enantiomer of piperazic acid may be similarly obtained starting with L-glutamic acid. The method may also be used to obtain piperazic acid derivatives that have moderate optical purity or are racemic. By this method, piperazic acid derivatives may be obtained that are useful as intermediates for pharmacologically active compounds. For example, certain intermediates of this invention are useful for preparing caspase inhibitors, particularly inhibitors of ICE, through additional steps known in the art.

    专利号:US-2003050305-A1
    优先权日:2000-05-22
    标题:Thromboxane inhibitors, compositions and methods of use
    发明人:TEJADA INIGO SAENZ DE
    摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Khalil A, Kashif M. Development of UV-visible spectrophotometric methods for the quantitative and in silico studies for cilazapril optimized by response surface methodology. Drug Dev Ind Pharm. 2021 Jul;47(7):1100-1111. doi: 10.1080/03639045.2021.1957918. Epub 2021 Aug 6. 25(14):3150. doi: 10.3390/molecules25143150.
    3: Regulska K, Regulski M, Wzgarda A, Kotowska A, Ignasiak A, Ćwiertnia B, Stanisz B. Does Polyvinylpyrrolidone Improve the Chemical Stability of Cilazapril in Solid State? Iran J Pharm Res. 2019 Spring;18(2):579-595. doi: 10.22037/ijpr.2019.1100640.
    4: Šljivic J, Protic A, Otaševic B, Golubovic J, Zecevic M, Krmar J. Multicriteria Optimization Methodology in Stability-Indicating Method Development of Cilazapril and Hydrochlorothiazide. J Chromatogr Sci. 2017 Jul 1;55(6):625-637. doi: 10.1093/chromsci/bmx018.

    合成参考文献


    参考文献:10.1007/s002280050137
    摘要:Larsen J, Sykulski R, Jensen G, Dössegger L, Trimarco B, Moccetti T, Glogar D, Schelling A, Bosma AH. Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment Comparison with long-term clinical effect. European Journal of Clinical Pharmacology. 1996 Jul;50(6):433–41. doi: 10.1007/s002280050137.
    参考文献:10.2165/00002018-199615010-00006
    摘要:Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996 Jul;15(1):72–8. doi: 10.2165/00002018-199615010-00006.
    参考文献:10.1007/bf02627956
    摘要:Covi G, Sheiban I, Gelmini G, Arcaro G, Tonni S, Bolner A, Piemonte G, Lechi A. Left ventricular diastolic function during adrenergic stress in essential hypertension: acute and chronic effects of ACE inhibition. Cardiovasc Drugs Ther. 1996 Jul;10(3):321–9. doi: 10.1007/bf02627956.
    参考文献:10.2165/00002018-199615030-00005
    摘要:Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf. 1996 Sep;15(3):200–11. doi: 10.2165/00002018-199615030-00005.
    参考文献:10.1007/s11886-002-0052-2
    摘要:Teerlink JR. The role of endothelin in the pathogenesis of heart failure. Curr Cardiol Rep. 2002 May;4(3):206–12. doi: 10.1007/s11886-002-0052-2.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知